initial public offerings (IPOs) trading on American exchanges
Showing posts with label Envision Healthcare (EVHC). Show all posts
Showing posts with label Envision Healthcare (EVHC). Show all posts

Monday, July 11, 2016

EVHC — is it a buy?

Envision Healthcare is an American healthcare company and national hospital based physician group. 
  • It has been a part of the S&P 500 index since December 2, 2016, where it replaced Legg Mason.
  • Reverse split on December 02, 2016. This was a 334 for 1000 reverse split, meaning for each 1000 shares of EVHC owned pre-split, the shareholder now owned 334 shares.


  • 2 years later

weekly


monthly

Wednesday, August 14, 2013

Envision Healthcare (EVHC) began trading on the NYSE on 14 August 2013


Clayton Dubilier & Rice-backed Envision Healthcare Holdings (EVHC) priced its upsized initial public offering at $23 per share, at the top of the expected $20 to $23 range, raising $966 million on Tuesday.

The Greenwood Village Colo.-based provider of outsourced medical and ambulance services sold 42 million shares; it had originally planned to offer 35 million shares. Private equity backer CD&R did not sell any shares in the IPO. At the IPO price, its stake of 128.9 million shares is valued at $2.96 billion.

That, added to the $428 million dividend Envision paid CD&R in October, brings the private equity firm's realized and unrealized gain to about 3.8 times the $887.1 million in equity it paid for the company in 2011, based on financial information in the company's filings.

CD&R acquired the company, then known as Emergency Medical Services Corp., in February 2011 in a deal valued at $3.2 billion. The acquisition was done via its Clayton, Dubilier & Rice Fund VIII, which closed in 2009 with $5 billion.

Envision's shares opened at $25.25 on its first day of trading; they traded up to a high of $25.69 by the afternoon.

The company said it will use proceeds of the IPO to redeem the outstanding $450 million principal amount of its PIK notes at about 102.75% of the principal amount plus accrued and unpaid interest, which it estimated to be around $17.2 million.

Envision posted adjusted EBITDA of $105.9 million on revenue of $899.3 million in the second quarter of 2013, up from adjusted EBITDA of $96.3 million on revenue of $801.1 million in the same quarter of the previous year.

Envision Healthcare listed on the New York Stock Exchange under the ticker symbol "EVHC." Goldman Sachs &, Barclays, Bank of America Merrill Lynch and Citigroup acted as the lead bookrunners on the deal.